CD8A and neoplasm: An oncolytic vaccinia virus expressing an IL-15 superagonist, a fusion protein of IL-15 and IL-15Ralpha, showed potent CD8+ T cell-dependent but NK independent anti-tumour responses in combination with anti-PD1 antibodies in mice challenged with colon or ovarian tumours[103].